7 completed. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
Follow MF59: new trials by email Literature Review of MF59 trials Research Report on MF59
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 372 | 2018-11-02 | 2021-05-17 |
| Panblok H7 Vaccine Adjuvanted With AS03 or MF59 3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7 - Influenza, Human | Phase 2 | Completed | Biomedical Advanced Research and Development Authority | 366 | 2017-09-20 | 2020-05-06 |
| Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant 7.5 mcg H5N1 (stored as monobulk), 15 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored as monobulk) - A/Vietnam/H5N1 Influenza Virus | Phase 2 | Completed | Biomedical Advanced Research and Development Authority | 422 | 2016-03-01 | 2020-08-31 |
| H7N9 Mix and Match With MF59 in Healthy Elderly Persons MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 - Avian Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 479 | 2014-10-01 | 2017-07-06 |
| H7N9 Mix and Match With MF59 in Healthy Adults Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59 - Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 700 | 2013-09-01 | 2016-12-12 |
| H7N9 Mix and Match With AS03 and MF59 in Healthy Adults AS03, MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 - Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 980 | 2013-09-01 | 2017-07-06 |
| Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients CAD106, Placebo, Alum - Alzheimer's Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 177 | 2010-03-01 | 2021-03-05 |
Influenza, Human (5) · Influenza in Birds (3) · Alzheimer Disease (1) · Central Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Orthomyxoviridae Infections (1) · RNA Virus Infections (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
National Institute of Allergy and Infectious Diseases (NIAID) (4) · Biomedical Advanced Research and Development Authority (2) · Novartis Pharmaceuticals (1)
United States (7) · Belgium (1) · Canada (1) · Germany (1) · Italy (1) · Netherlands (1) · Norway (1) · Spain (1) · Sweden (1) · Switzerland (1)
Carlos Fierro, MD (1) · Mark Adams, MD (1) · Matthew Davis, MD (1) · Terry Poling, MD (1)
PMID 25291577, PMID 26197184, PMID 36273986, PMID 39798434
2009 (1)